TRAIL mediated signaling in different cancers: cancer in the Crosshairs

Basit Öğe Kaydı
dc.authoridAttar, Rukset/0000-0001-8770-9562
dc.authoridUteuliyev, Yerzhan/0000-0002-0377-8315
dc.contributor.authorFarooqi, Ammad Ahmad
dc.contributor.authorNaureen, Humaira
dc.contributor.authorYilmaz, Seher
dc.contributor.authorSabitaliyevich, Uteuliyev Yerzhan
dc.contributor.authorZhailganov, Azamat
dc.contributor.authorRabandiyarov, Marat
dc.contributor.authorUcak, Ilknur
dc.date.accessioned2024-11-07T13:35:02Z
dc.date.available2024-11-07T13:35:02Z
dc.date.issued2020
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractCancer is a therapeutically challenging disease because of its heterogeneous and multifaceted nature. Decades of research have sequentially and systematically enabled us to develop a sharper and better understanding of the heterogeneous nature of cancer. Genetic, genomic and proteomic studies have unraveled wide-ranging signaling cascades which play cornerstone role in disease onset and progression. More importantly, activation of pro-survival signaling and loss of apoptosis also play critical role in cancer progression. TRAIL-mediated signaling pathway has emerged as one of the most comprehensively analyzed cascade because of its exceptional ability to target cancer cells while leaving normal cells intact. TRAIL discovery and landmark achievements related to TRAIL/TRAILreceptor signaling pathway attracted the attention of researchers. Therefore, scientists started to add missing pieces to an incomplete jig-saw puzzle and allowed contemporary researchers to conceptualize a better molecular snapshot of TRAIL-induced signaling in various cancers. Circumstantial evidence illuminated a functionally unique push and pull between anti-apoptotic and pro-apoptotic proteins in different cancers. Overexpression of anti-apoptotic proteins and inactivation of pro-apoptotic proteins shifted the balance towards loss of apoptosis. There has been a breakneck increase in the number of clinical trials related to TRAIL-based therapeutics which validate the true pharmacological potential of TRAIL-based therapeutics as effective anticancer agents. However, apart from advancements in our clinical understanding about the efficacy of TRAIL-based therapeutics, researchers have also faced setbacks in the field of translational medicine. Therefore, in this review, we have attempted to set spotlight on the most recent and landmark discoveries which have leveraged our understanding related to TRAIL-mediated signaling altogether to a new level.
dc.identifier.doi10.14715/cmb/2020.66.8.1
dc.identifier.endpage8
dc.identifier.issn0145-5680
dc.identifier.issn1165-158X
dc.identifier.issue8
dc.identifier.pmid34174975
dc.identifier.scopus2-s2.0-85103147305
dc.identifier.scopusqualityQ4
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.14715/cmb/2020.66.8.1
dc.identifier.urihttps://hdl.handle.net/11480/16299
dc.identifier.volume66
dc.identifier.wosWOS:000616810100001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherC M B Assoc
dc.relation.ispartofCellular and Molecular Biology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectTRAIL
dc.subjectCancer
dc.subjectApoptosis
dc.subjectSignaling
dc.titleTRAIL mediated signaling in different cancers: cancer in the Crosshairs
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu